ABK Biomedical Board of Directors
Dr. Berez is Chairman of the ABK Biomedical Board of Directors. He is the founder and CEO of Alembic, LLC, a medical device development company in Mountain View developing new devices for Interventional Neuroradiology. Cathera, Inc, an Alembic company, developed a suite of microcatheters optimized for intracranial navigation. Cathera was acquired by Medtronic in 2018. Palmera, Inc, an Alembic company, is developing new technologies for the minimally invasive treatment of stroke that have the potential to improve outcomes for patients that are currently treated, as well as widen the scope of patients that can benefit from therapy.
At his previous company, Chestnut Medical, he led the development of the Pipeline Embolization Device for the treatment of complex intracranial aneurysms. In 2012, Pipeline was recognized as a top ten medical device innovation by the Cleveland Clinic. Today, it is being used to treat aneurysm patients all over the world and represents a $150MM annual franchise for Medtronic. Chestnut Medical was acquired by ev3 in 2009. Prior to that Dr. Berez worked at Smart Therapeutics where he helped develop the Neuroform and Wingspan intracranial stents, and Endovasix.
Dr. Berez is currently an investor, advisor, and director to privately held medical device companies focused on capital-efficient medical device development. He is a graduate of the Georgetown University School of Medicine, where he received his MD degree. His postgraduate training was at UCSF/Mt. Zion in Internal Medicine, and Stanford University in Radiology and Neuroradiology.
James McLaren is a Managing Director of TM Capital Corp. a middle-market investment bank, where he is co-head of the firm’s healthcare practice. He brings an extensive background in corporate finance and the healthcare industry to ABK Biomedical’s Board. James joined TM Capital from Asante Partners, which he founded more than twenty years ago to provide quality strategic advice to middle-market healthcare companies. Previously, James had a twenty-year career advising corporate clients at Goldman, Sachs & Co. where he served as head of European Corporate Finance in London and of International Corporate Finance in New York, leading teams that executed significant global transactions.
James is a director of CorVista Health, based in Toronto and Washington DC, that is developing a machine learning-based cardiac diagnostic platform to provide rapid, non-invasive tests to diagnose multiple cardiovascular conditions, including coronary artery disease, heart failure, and pulmonary hypertension. James is also an advisory board member of Radius Ventures, a New York-based firm focused on the healthcare industry, and was a director of Montreal-based RTP Pharma until its sale to Skye Pharma. James earned a BA with Honors in Economics from Oxford University, UK.
President and Chief Executive Officer
Mike Mangano is the President and CEO of ABK Biomedical. Mike is an accomplished global executive leader with over 25 years’ experience in the medical device industry. Over this time, he served as a member of senior leadership and executive committees and has a long history of success in building dynamic teams, leading organizational change, creating and shaping strategies, and executing programs leading directly to increased shareholder value. These accomplishments include his recent role as CEO of ReShape Medical, and his success in growing Sirtex Medical, an Interventional Oncology medical device manufacturer, from $34 million in revenue to over $130 million, during his six-year term as President of the Americas.
Prior to his role at Sirtex Medical, Mike served 15 years at Boston Scientific, where he functioned in many key roles and most recently as Director of International Distribution Management. Mike brings pragmatic leadership to ABK with his vast experience in sales/marketing management, product development, strategic planning, international business, M&A, project management, and business model development. His experience and guidance will help take ABK Biomedical to the next level in delivering commercial excellence for our customers and the patients that will benefit from our innovative products.
Ketan Patel is a Partner with F-Prime Capital and has worked in the healthcare sector as an investor, consultant, and physician. Prior to joining F-Prime Capital in 2007, Dr. Patel advised biopharmaceutical and medical device companies on brand strategy, clinical development plans, and business development activities in the corporate consulting division of Leerink Swann & Company. Dr. Patel served as a physician at the VA Boston Healthcare System and at Weill Cornell Medical Center-New York Presbyterian Hospital and Memorial-Sloan Kettering Cancer Center where he completed his internal medicine training
Dr. Patel focuses on investing in therapeutics and medical device companies and has served on the Board of Directors of ABK Biomedical, Aclaris Therapeutics (NASDAQ:ACRS), Avalyn Pharma, Caplin Steriles, Comanche Biopharma, Eywa Pharma, Ivenix, Laurus Labs (NSE:LAURUSLABS), Medwell Ventures, Menlo Therapeutics (NASDAQ:MNLO), NextWave Pharmaceuticals (acquired by Pfizer), NFlection Therapeutics, Pediatrix Therapeutics, Rallybio (NASDAQ:RLYB), Vicept Therapeutics (acquired by Allergan). Dr. Patel is a graduate of Tufts University School of Medicine, where he received both his MD and MBA as part of that institution’s Healthcare Management Program and was elected to the Alpha Omega Alpha Medical Honor Society. He completed his undergraduate studies in biology and economics with highest honors at Rutgers University..
PJ Bullock is a VP of Strategy and Business Development for Varian Medical Systems where he has served within the Strategy & Corporate Development function for almost a decade. Varian, headquartered in Palo Alto, California, is focused on combining the ingenuity of people with the power of data and technology to achieve new victories against cancer. PJ’s influence on Varian’s continued growth is driven by his proven leadership in managing company-wide planning processes, executing complex strategic transactions, and facilitating investments in expansion initiatives.
During his time at Varian, PJ completed over two dozen transactions in 10 countries that directly contributed to Varian’s efforts in cancer therapy, clinical workflow solutions, data analytics, imaging, care delivery, and professional services. His broad background in various oncology related fields brings a level of specialized expertise in M&A, project management, market assessment, and deal structuring to the ABK Board. Mr. Bullock has also represented Varian as an observer to the Boards of Augmenix, Inc. (acquired by Boston Scientific in Sept. 2018) and Oncora Medical, Inc.
Halifax Office (Main Office)
155 Chain Lake Drive
Halifax, NS B3S 1B3
Orange County Office
555 Corporate Drive
Ladera Ranch, CA, 92694
ABK Biomedical Inc. provides and continues to provide accurate information on its website. However, ABK Biomedical Inc. assumes no responsibility for the accuracy and/or completeness, express or implied, as to the information contained or omitted and/or the products described. Furthermore, ABK Biomedical Inc. may change the products mentioned, and their stage in development, at any time without notice. ABK Biomedical Inc. is a clinical-stage company engaged in the research and development of new medical devices. ABK Biomedical inc. products are considered investigational products and are NOT FDA approved for use. Y90 radioembolization
(C) Copyright 2021 - All International Rights Reserved